Xenon Pharmaceuticals, which licenses drugs to uniQure, Teva and Genentech for LPLD, pain and acne, relaunched its IPO on Monday, two weeks after initially postponing its deal in. The Burnaby, Canada-based company still plans to raise $44 million by offering 4 million shares at a price range of $10 to $12. At the midpoint of the proposed range, Xenon Pharmaceuticals would command a fully diluted market cap of $158 million.
Xenon Pharmaceuticals, which was founded in 1996 and booked $27 million in sales for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol XENE. Xenon Pharmaceuticals initially filed confidentially on 8/16/2013. Jefferies & Co. and Wells Fargo Securities are the joint bookrunners on the deal.
The article Xenon Pharmaceuticals relaunches $44 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.